ACC-2 human protein
- Known as:
- ACC-2 H. sapiens protein
- Catalog number:
- 50199
- Product Quantity:
- 10
- Category:
- -
- Supplier:
- BPS Bioscience
- Gene target:
- ACC-2 human protein
Related genes to: ACC-2 human protein
- Gene:
- ACACB NIH gene
- Name:
- acetyl-CoA carboxylase beta
- Previous symbol:
- -
- Synonyms:
- HACC275, ACC2, ACCB
- Chromosome:
- 12q24.11
- Locus Type:
- gene with protein product
- Date approved:
- 1996-12-18
- Date modifiied:
- 2016-10-05
- Gene:
- BCL2A1 NIH gene
- Name:
- BCL2 related protein A1
- Previous symbol:
- HBPA1
- Synonyms:
- GRS, BFL1, BCL2L5, ACC-1, ACC-2, ACC2, ACC1
- Chromosome:
- 15q25.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-05-08
- Date modifiied:
- 2016-10-05
- Gene:
- SMARCC2 NIH gene
- Name:
- SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily c member 2
- Previous symbol:
- -
- Synonyms:
- BAF170, Rsc8, CRACC2
- Chromosome:
- 12q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1998-05-15
- Date modifiied:
- 2016-11-09
Related products to: ACC-2 human protein
Related articles to: ACC-2 human protein
- Trigeminal neuralgia (TN) is relatively prevalent among the elderly population. Mitochondria-regulated programmed cell death has been identified as an important mechanism in the pathogenesis of a series of diseases; however, its role in TN remains poorly understood. This study aimed to uncover mitochondria-related genes (MRGs) and programmed cell death-related genes (PCDRGs) implicated in TN and elucidate their potential mechanisms. - Source: PubMed
Publication date: 2026/06/24
Gao LiqinShi HongchenXi LuluLiu XiaohuiRen YueWang Qiujun - Breast cancer is the most prevalent malignant tumor in women globally, with its prognosis linked to immune responses, especially CD8 + and CD4 + T cell infiltration. T cell exhaustion, an immune dysfunction seen in chronic infections and cancers, is not well understood in breast cancer. This study seeks to investigate the role and prognostic significance of genes related to T cell exhaustion in breast cancer through bioinformatics, offering insights into the mechanisms of T cell exhaustion in this disease. - Source: PubMed
Publication date: 2026/06/29
Guo LianheChen XiangjinZhou Fan - Breast cancer (BRCA) is a common malignant tumor that seriously threatens women's health. Studies have shown that histone modifications (HMs) play a vital role in the occurrence and development of BRCA. This study aims to explore the distribution patterns of HMs in the mammary epithelial cell line (HMEC) and breast cancer cell line (MCF-7), and their potential associations with gene expression, patient prognosis, and drug efficacy. - Source: PubMed
Publication date: 2026/06/01
Cao YanniLi XiaohuiLiu JiangshanZhang JunyuanXu KangchengLin HaoLiu Yuxian - The BCL-2 protein family controls the intrinsic apoptotic pathway through a delicate balance of pro- and anti-apoptotic members acting at the mitochondrial outer membrane. Anti-apoptotic proteins BCL-2, BCL-XL, MCL-1, BCL-W, and BCL2A1 (BFL-1) function as critical survival factors whose dysregulation contributes to cancer development and therapeutic resistance. This review systematically examines the multilayered regulatory mechanisms governing these proteins, including transcriptional control by NF-κB, STAT3/5, and HIF-1α; post-transcriptional regulation through alternative splicing and microRNAs; and post-translational modifications that determine protein stability and function. The clinical success of venetoclax, a selective BCL-2 inhibitor, has established BCL-2 family targeting as an effective therapeutic strategy and fundamentally changed the management of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, therapeutic challenges persist: resistance emerges through MCL-1 upregulation, BCL-2 mutations, and metabolic reprogramming; BCL-XL inhibition causes dose-limiting thrombocytopenia; and MCL-1 inhibitors face class-wide cardiac toxicity. Emerging strategies to overcome these limitations include tissue-selective proteolysis-targeting chimeras (PROTACs) and antibody-drug conjugates (ADCs) enabling tumor-targeted delivery, next-generation inhibitors that overcome resistance mutations, and biomarker-guided patient selection. This review provides an integrated overview of the regulatory mechanisms and evolving therapeutic strategies targeting anti-apoptotic BCL-2 family proteins, outlining both prominent successes and unresolved challenges. - Source: PubMed
Publication date: 2026/06/03
Wang ZheTang MutianKonopleva Marina - This study aimed to develop a robust predictive model and nomogram for breast cancer (BC) based on genes associated with diverse cell death methods. A prognostic model was constructed using the LASSO Cox method, incorporating twelve genes (CREB3L1, SFRP1, SHARPIN, AIFM1, IL‑18, CD24, EDA2R, CRIP1, XBP1, BCL2A1, NKX3‑1, and NME5). BC patients were classified into high‑risk and low‑risk subgroups, with the low‑risk subgroup showing superior survival, and this prognostic value was validated in an independent external cohort. A nomogram was also developed and confirmed as a reliable independent predictor of outcome. Enrichment analyses suggested a link between patient risk and immune response. The low‑risk subgroup exhibited a higher tumor microenvironment (TME) score. Patients in the high‑risk group showed improved responses to lapatinib, BI‑2536, OSI‑027, and SB505124, whereas those in the low‑risk subgroup had better sensitivity to axitinib, epirubicin, fulvestrant, and olaparib. Additionally, CD24 overexpression in BC cell lines promoted proliferation and migration, and inhibited apoptosis. These findings contribute to personalized treatment strategies and help elucidate the tumor microenvironment characteristics of BC patients. - Source: PubMed
Wu RihanWang ZiruiBai YuanruiDong ChunhuiLiu YihuiChen Ling